Printer Friendly

INCSTAR FINALIZES DISTRIBUTION ALLIANCE WITH CENTOCOR DIAGNOSTICS

   INCSTAR FINALIZES DISTRIBUTION ALLIANCE WITH CENTOCOR DIAGNOSTICS
    STILLWATER, Minn., Nov. 13 /PRNewswire/ -- INCSTAR Corporation (ASE: ISR) today announced completion of a North American distribution agreement for certain Centocor-manufactured tumor marker immunodiagnostic tests.  The agreement grants INCSTAR semi-exclusive sales and marketing rights over the next five years to Centocor's CA 125(TM) RIA Serum Tumor Marker kit and other kits receiving regulatory approval, in exchange for cash payments totaling $2.7 million over the next two years.  Orwin L. Carter, president and CEO of INCSTAR said, "This agreement provides INCSTAR with an entry into the rapidly growing tumor marker segment of the immunodiagnostic market."
    INCSTAR is a Minnesota-based manufacturer and distributor of high quality immunodiagnostic products for health care professionals and manufacturers.  The company is an affiliate of the Italian-based Fiat Group (NYSE: FIA).
    Centocor Diagnostics is a division of Centocor Inc. (NASDAQ: CNTO), based in Malvern, Pa.  Centocor Diagnostics is a leader in monoclonal antibody technology and supplies 25 percent of the world market for cancer immunodiagnostics.
    -0-                   11/13/91
    /Contact:  Jack Falker of Swenson/Falker Associates Inc., 612-371-0000, or John Booth, of INCSTAR Corp., 612-779-1700 or Richard Koening, of Centocor, 215-651-6122/
    (ISR FIA CNTO) CO:  INCSTAR Corporation; Fiat Group; Centocor Diagnostics ST:  Minnesota, Pennsylvania IN:  MTC SU:  CON AL -- MN003 -- 3795 11/13/91 09:22 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 13, 1991
Words:219
Previous Article:NOVO NORDISK A/S REPORTS NINE MONTH AND THIRD QUARTER 1991 RESULTS
Next Article:DATARAM RECORDS 114 PERCENT EARNINGS INCREASE IN SECOND QUARTER OF FISCAL 1992
Topics:


Related Articles
CENTOCOR REPORTS RESULTS OF OPERATIONS FOR THE QUARTER ENDED SEPT. 30, 1991
CENTOCOR AND CORVAS SIGN ANTIBODY AGREEMENT
INCSTAR REPORTS 55 PERCENT INCREASE IN FOURTH QUARTER EARNINGS
SUIT FILED SEEKING TO BLOCK EXCHANGE OFFER FOR TOCOR II UNITS
CENTOCOR TO HOLD CONFERENCE CALL TO DISCUSS THIRD QUARTER RESULTS
CENTOCOR REPORTS FIRST QUARTER 1996 FINANCIAL RESULTS
CENTOCOR ANNOUNCES POSITIVE RESULTS FOR PHASE II CROHN'S DISEASE TRIAL
Centocor to Settle Litigation
Centocor Names Veteran Industry Executive to Head Diagnostics Division
Genzyme Transgenics to Develop Transgenic Monoclonal Antibodies for Centocor.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters